Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;103(1):112-119.
doi: 10.1002/cpt.930. Epub 2017 Nov 28.

Buprenorphine in Neonatal Abstinence Syndrome

Walter K Kraft  1
Affiliations
Review

Buprenorphine in Neonatal Abstinence Syndrome

Walter K Kraft. Clin Pharmacol Ther. 2018 Jan.

Abstract

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

Dr. Kraft has served as an unpaid consultant to Chiesi Farmaceutici S.p.A.

Figures

Figure 1
Figure 1
Model-based developmental trajectory of neonatal postnatal age compared to adult clearance of buprenorphine. PNA, postnatal age.
Figure 2
Figure 2
Model-based developmental trajectory of neonatal postnatal age compared to adult peripheral volume (V3) of buprenorphine. PNA, postnatal age.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goasdoue K, Miller SM, Colditz PB, Bjorkman ST. Review: the blood-brain barrier; protecting the developing fetal brain. Placenta. 2017;54:111–116. - PubMed
    1. Bauer CR, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch. Pediatr. Adolesc. Med. 2005;159:824–834. - PubMed
    1. Salisbury AL, et al. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am. J. Psychiatry. 2016;173:147–157. - PMC - PubMed
    1. Jones HE, et al. Cigarette smoking in opioid-dependent pregnant women: Neonatal and maternal outcomes. Drug Alcohol Depend. 2013;131:271–277. - PMC - PubMed
    1. Food and Drug Administration. [Accessed 6 September 2017];FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011 < https://www.fda.gov/Drugs/DrugSafety/ucm243903.htm>.

MeSH terms

LinkOut - more resources